Cancer is a growth industry. And drug companies are not interested in curing cancer. It is more profitable to turn it into a chronic condition. They can then offer “chronic treatments.” Patients will keep coming back for expensive treatments.
This isn’t idle speculation. In April 2018, Goldman Sachs, a Wall St. bank with almost one trillion dollars in assets, let the cat out of the bag. A top level employee named Salveen Richter issued a report advising clients to think twice before offering actual cures for cancer or hepatitis C.
Ms. Richter is no wild-eyed conspiracy theorist. She is Vice President of Goldman’s Research Division and a graduate of Johns Hopkins University.
The report is titled “The Genome Revolution.” In it, Richter worries that the genetic revolution might be too effective at eliminating disease. She asks a rhetorical question: “Is curing patients a sustainable business model?”
Her answer is, No. She suggests that companies think twice before offering treatments that actually cure people! CNBC quotes her report:
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies. While this proposition [of one-shot cures] carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
“Sustained cash flow.” That’s Big Pharma’s bottom line. But this is so blatant! They used to hide this stuff. If you dared to point out that their only interest was in making money off of cancer and other diseases, you were called a tin foil hat nut job, a conspiracy theorist, and all the rest.
But now it’s all out in the open. Because what the public thinks doesn’t really matter, and least of all to them.
But now we’ve got to focus on our own needs and not be afraid to go against these people and expose them whenever we can. Because, if we don’t, we’re going to be the ones who will pay the price. In money, to be sure, but also in terms of misery and ill health.